Welcome ZICO - Thank you for your posts which have been very helpful and a breath of fresh air. I do think it is time to buy more on the PRM statement and that the move to America is apparently going so well. I am also encouraged by the £500,000 contract awarded, with the prospect of more from that same company and contracts from others. However many us who have been bulls over the years have been disappointed so often. Maybe this is the moment for PRM to move forward and enjoy the momentum of the Proteomic market growing into the future. PRM certainly have some good products and we are in the right area. Hopefully Stroke may come good to this year. How I would love to see this. |
They also have a laboratory in San Diego , California which was NOT around in 2022 when they had a record year.
The share price will rerate massively in 2025.
It's all about the future prospects and NOT what happened over the last decade! |
My post is not bearish but realistic! |
049balt
If you take time and read the interim results and the last trading update , you will NOT be posting bearish comments like the one above.
The slowdown which the company experienced in 2023 and 1st half of 2024 is clearly finished and the company is trading very strongly and this momentum will continue into 2025 and 2026.
The company is experiencing huge growth and had to buy 2 more mass spectrometers to cope with the huge demand of orders.They have stated that they will be buying another mass spectrometer. |
Because of the history we will have to see actual figs before we see any re rating. Nobody is going to speculate on future earnings after decades of disappointment. We need to see serious traction before we get out of this rut |
 I keep going on about 2025 will most likely be another record year for revenue and profits , let me elaborate further regarding this:
In the recent trading update there was no mention of the actual revenue for 2024 but reading the interim results the CEO indicated that 2024 TMT revenue will be considerably ahead of 2023.
Total revenues for 2023 was £5.03m (2022: £7.78m)
Proteomic services revenues of £1.63m (2022: £2.75m)
TMT® sales, and royalties of £3.40m (2022: £4.16m)
For the 6 months to 30/06/2024:
Total revenues £2.22m (H1 2023: £3.21m)
TMT® reagent sales and royalties £1.85m (H1 2023: £2.20m)
Proteomics services revenues £0.37m (H1 2023: £1.01m)
H2 revenue for TMT will be very strong compared to H1 and full year TMT revenue for 2024 will be considerably higher than 2023 which was £3.40m.
Total Proteomics services revenue for 2024 will also be very strong when comparing this years H1 and for 2023:
In April 2024 the company announced a substantial GCLP based contract with a US biopharma company. It is now regularly receiving clinical samples from their trial centres with service revenue to be recorded in both 2024 and 2025. This order made a significant impact to the orders received in H1 2024, overall we received 75% more orders and 2.8x greater value compared to the same period in 2023. The company is working on several other assay development contracts with the same biopharma company which are anticipated to lead to further contracts for GCLP analysis early in 2025.
+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
From the above;
Full year revenue for 2024 will be apprx £6.1m
TMT revenue of apprx £4.25m
Services revenue of apprx £1.85m
+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
The above revenue number for TMT is based on only 25% growth over 2023 and the CEO has indicated that TMT revenue will be CONSIDERABLY higher than 2023.
Does considerably higher mean 25% or even more ???
Once we get further news from the company about the actual numbers for 2024 and further outlook for 2025 the shares will rerate significantly higher and at some point in 2024 RISE in excess of 10p and a lot higher in 2025. |
For year ending 31/12/2022 when the company generated record revenue and profits of £7.78m and profits of £1.33m they did NOT even a laboratory in the US , which is the worlds biggest market.
The opening of the US laboratory is very significant for the company because for US based clients who did not previously want to ship their samples to Europe this has now enabled the company to be eligible for projects funded by US institutions where the funds must be spent in the US.
Another record revenue and profits is on the cards for 2025.
Short video of US laboratory in San Diego, California: |
By the time full year results are announced the share price will be considerably higher from the current levels. |
What did Mariola achieve in her tenure,4 years,£1m in wages,destroyed the share price and SFA in return.Jeremy the same.Might as well of had CJP at the helm and saved a few million £££.And the New pools is expecting what exactly???,leopards don't change their spots.Was this the plan all along?? |
Share price fell from the highs of 9p in August 2023 to around 2.5p in September 2024 on deteriorating trading conditions in the sector.
With the company once again trading very strongly the downtrend is well and truly behind us.
A new bull run has started and will continue throughout 2025 and 2026.
A rerate to 9p - 10p in 2025 and a lot higher in 2026. |
US facility first anniversary yesterday:
Proteome Sciences has announced that it has completed the installation and set up of equipment in its new laboratory facility in San Diego, US, meaning it is now fully operational.
The new facility utilises the latest Orbitrap Ascend Tribrid mass spectrometry and automated sample preparation platforms that will “extend the range of services offered to customers,” according to the company’s press release.
This facility is based within one of the US’s largest biotech hubs, which has received investments of a combined $17.2bn as well as National Institute of Health (NIH) funding of $6bn in 2022-2023.
The press release explains that Proteome’s new facility is intended to “serve demand from a growing number of US customers looking to outsource proteomics projects to underpin their drug development programmes.”
Dr Ian Pike, president of Proteome Sciences US, commented: “I am delighted that we are able to open our doors to serve arguably the world’s largest biotechnology hub in California. Providing easier access to our US customers and with innovations including TMTpro 32plex and single cell proteomics (SCP), delivered from both our dedicated laboratories in the US and Europe we are well set to continue our leading role in provision of tools, assays and services in proteomics research as it grows in importance to enhance pharmaceutical research and drug development.” |
Does the tau protein associated with Alzheimer’s help battle herpes in the brain?
Despite decades of study, neuroscientists aren’t sure exactly why some people develop the clumps of β-amyloid and tangles of phosphorylated tau proteins that are the hallmarks of Alzheimer’s disease. Now, a study adds to the support for a controversial hypothesis that viruses, especially those that cause herpes, may exacerbate or even trigger the neurodegenerative disease.
Herpes simplex virus 1, or HSV-1 for short, is generally milder than its relatives, causing mere cold sores. But it can make its way into the brain, and some have hypothesized this may set off a chain reaction that ultimately leads to the death of neurons. To further investigate this idea, researchers looked for HSV-1 proteins in postmortem brain samples from people with and without Alzheimer’s disease. They found bits of the virus in the same places as phosphorylated tau, suggesting an association. When they introduced the virus into cultured mini-brains grown from stem cells (known as organoids), levels of tau increased—and this rise helped suppress the infection.
“Our study challenges the conventional view of tau as solely harmful, showing that it may initially act as part of the brain’s immune defense,” said senior author Or Shemesh in a statement. And it could point towards new avenues of Alzheimer’s prevention—although much more research on the connection between HSV-1 and the disease is needed before the findings could be translated clinically.
hxxps://www.cell.com/cell-reports/fulltext/S2211-1247(24)01460-8?et_rid=1097484510&et_cid=5482183 |
A few buys this morning has pushed the buying price to 3.77p even for just 10,000 shares |
A full year trading update with some numbers will help.
There is no doubt that trading in H2 has been very strong and could well have been ahead of expectations.
Due to substantial increase in orders the company has bought TWO mass spectrometers during H2 and about to buy ONE more.
The outlook is looking good for 2025 and onwards.
Share price will multibag in 2025 from the current levels like it did in 2023. |
Last weeks RNs was positive in respect of substantially improved H2 trading & it will be interesting to see if a more detailed trading update is published in the next week or two referring specifically to FY24 revenues & expected profitability-especially if we have exceeded previously reduced expectations. |
Being quoted 3.71p to buy up to 62500 , 3.918p to buy up to 100,000 and 4.1p for above 120,000. |
The substantial increase in services orders required the company to acquire two additional mass spectrometers that came on stream during the year to provide additional capacity but these were still not enough to satisfy the current demand in the pipeline that has extended out to 2026 from additional customer contracts that have been secured.
Year ending 31/12/2022 was a record for revenue and profits , £7.78m and profit after tax of £1.33m.
After the strongly worded update it looks like 2025 will be another record year for revenue and profits.
The shares at 3.5p are a VERY STRONG BUY |
Key Players Covered In This Report:
◘ Noble Life Sciences Inc.
◘ Reprocell Corporation
◘ Coriell Institute
◘ BioIVT
◘ ICON Plc.
◘ SRI International Inc.
◘ Charles River Laboratories Inc.
◘ Nordic Bioscience A/S
◘ Proteome Sciences Plc.
◘ Covance Inc. (Laboratory Corporation of America Holdings Inc.) |
Proteomics Market Analysis, Driving Innovation in Biomedical Research | Exactitude Consultancy
December 16, 2024
The global proteomics market growth forecasted to transform from USD 30.6 billion in 2024 to USD 64.11 billion by 2031, driven by a CAGR of 11.87%.
Luton, Bedfordshire, United Kingdom, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The proteomics market is experiencing robust growth driven by several key factors. One of the primary drivers is the increasing demand for personalized medicine, which is reshaping clinical practices and enabling tailored treatments. The use of proteomics in drug discovery and development is also expanding, with the growing emphasis on discovering new biomarkers for disease diagnosis and treatment, as well as optimizing drug efficacy and safety.
Access PDF Sample Report (Including Graphs, Charts & Figures) @
Moreover, substantial investments from both government and private sectors are fueling innovation in proteomics technologies. Clinical trials and translational research are benefitting from proteomics' ability to deliver insights that accelerate the development of novel therapies. In particular, the development of biologics and biosimilars is heavily reliant on proteomic techniques to ensure product quality and effectiveness.
There is also an increasing focus on monoclonal antibodies and therapeutic proteins, with proteomics playing a critical role in the characterization and optimization of these biologic therapies. The advancements in protein quantification techniques, including mass spectrometry and other high-throughput methods, are improving the accuracy and efficiency of protein analysis, further contributing to market growth.
In addition, single-cell proteomics has emerged as a significant area of interest, offering new insights into cellular functions and disease mechanisms at an unprecedented resolution. Coupled with the growth of bioinformatics, these advancements are driving innovation and providing deeper insights into complex biological systems.
The proteomics market is expected to reach a market value of $30 billion by 2026, with a compound annual growth rate (CAGR) of approximately 10%, driven by these factors and the ongoing expansion of applications across various sectors, from diagnostics to therapeutic development.
Proteomics Market Dynamics
Driver: Rising Demand for Personalized Medicine
The proteomics market is significantly benefiting from the growing demand for personalized medicine, which enables treatments tailored to individual patients. By providing deep molecular insights, proteomics allows for the discovery of biomarkers, identification of drug targets, and tracking of therapeutic responses, all of which support the development of targeted therapies. Over the past decade, personalized medicine has gained tremendous traction, with FDA approvals reflecting the increasing market need. For instance, in 2021, the FDA's Center for Drug Evaluation and Research approved 50 new molecular entities (NMEs), primarily focusing on therapeutic products. In 2022, 37 NMEs were approved, further showcasing the ongoing expansion in this domain. As personalized medicine continues to advance, proteomics is poised to play an even more significant role in the healthcare landscape, driving the need for more sophisticated analytical technologies. |
!FOLLOWFEED
A new thread for 2025 onwards.
Share price will rerate significantly in 2025 by at least 300% and will RISE above 10p again.
The company is poised to experience substantial growth , the strong trading in H2 of 2024 mentioned in the recent trading update will continue throughout 2025 and 2026.
Trading Update
23/12/2024
In the Interim Results, the Company detailed a strong increase in orders for both the TMT and its services business and is pleased to confirm that momentum has continued through the second half. In particular, the strong growth in the Company's services business orders has carried over into the 2025 and 2026 pipeline and the Board expects this to be reflected in the 2025 results.
The TMTpro 35plex tags which launched in June resulted in a significant increase in orders and should stimulate new publications that demonstrate the outstanding performance of the tags and their utility, which should further improve uptake and usage. Good progress is being made with the Company's new multiplexed DIA tags, with discussions underway with a shortlisted group of prospective licensees expected to conclude in H1 2025. The Company is also processing its first commercial orders in single cell proteomics (SCP) and the outcomes are awaited with great interest.
The substantial increase in services orders required the Company to acquire two additional top-end mass spectrometers that came on stream during the year to provide additional capacity but these are still not enough to satisfy the current demand in the pipeline that has extended out to 2026 from additional customer contracts that have been secured. Proteome Sciences needs to increase the instrument capacity further.
Proteome Sciences will use the Loan Facility to facilitate the acquisition of a new Exploris mass spectrometer to further expand its capacity for future orders and to provide additional working capital at this inflection point in the Company's services business.
The full year outcome in 2024 is expected to show good recovery from the impact of the global downturn in biotech over the previous year and the first half of this year. Based on the considerable increase in customer orders and services in the second half of the year, we are optimistic that our proteomics business can deliver substantial increases in revenue and returns in the future. |
Very quite , must be due to the very large spread |
Remember years ago Proteome commissioned their own report on the market and what their share of it may be.They couldn't get within 1% of it,so all these other report's that pop up on your junk mail are meaningless Zico/pools. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
